Get the Daily Brief
Latest Biotech News
DNA-Based Neural Networks Demonstrate Supervised Learning Capabilities
Caltech researchers have engineered a neural network constructed from DNA strands, marking a leap in biochemical computing. Unlike electronic neural networks, this DNA-based system performs...
AI-Driven Virtual Cell Models Propel Cancer Research and Drug Development
Researchers led by Yang, T. and Wang, YY have unveiled an artificial intelligence approach that creates virtual cell models simulating intricate human cellular behaviors. These models enable...
Novartis Upfronts $200M for Arrowhead RNAi Parkinson’s Candidate
Novartis has entered a significant licensing and collaboration agreement with Arrowhead Pharmaceuticals, investing $200 million upfront to develop Arrowhead's preclinical siRNA therapy targeting...
Ionis’ Olezarsen Cuts Triglycerides, Acute Pancreatitis in Severe Hypertriglyceridemia
Ionis Pharmaceuticals announced positive results from two pivotal Phase 3 trials demonstrating that olezarsen markedly reduced fasting triglycerides by up to 72% and decreased acute pancreatitis...
Amgen Commits $600 Million to New California Science and Innovation Center
Amgen has announced plans to invest over $600 million to build a state-of-the-art center for science and innovation at its Thousand Oaks global headquarters. The facility will consolidate...
Treeline Biosciences Discloses $200M Round, Names First Clinical Candidates
Treeline Biosciences announced a $200 million series A extension, totaling $1.1 billion raised to date, alongside unveiling its first three clinical-stage oncology candidates. The company’s...
Fiber-seq Multiomics Assay Reagents Comarketed by PacBio and EpiCypher
Pacific Biosciences and EpiCypher have entered a comarketing agreement for the Cutana Hia5 methyltransferase enzyme, a key reagent in the Fiber-seq assay. Fiber-seq leverages enzymatic DNA...
NeoGenomics Wins Patent Suit, Advances Radar MRD Commercialization
NeoGenomics achieved a key legal victory as the Middle District of North Carolina invalidated Natera’s patents underpinning its Signatera assay, enabling NeoGenomics to resume commercialization of...
Novel Protein Therapeutic 'Crunch' Reprograms Immune Clearance of Harmful Cells
Kyoto University researchers have engineered a synthetic protein named Crunch that reprograms the phagocytic immune system to selectively eliminate living harmful cells, such as cancer or...
Mercy BioAnalytics Raises $59M to Commercialize Early Cancer Detection Tests
Mercy BioAnalytics secured $59 million in Series B funding to advance commercialization of its blood-based ovarian cancer test panel that detects tumor-specific proteins on extracellular vesicles....
Upstream Bio Posts Phase 2 Win in Sinusitis Amid Market Skepticism
Upstream Bio announced positive Phase 2 data for its candidate verekitug in sinusitis treatment, meeting study endpoints. Despite this clinical success, investor enthusiasm has been muted due to a...
FDA Regulatory Updates and Clinical Trial Approvals for Early September 2025
Recent regulatory developments include approvals, designations, and submissions for various drugs and medical devices spanning oncology, infectious diseases, and diagnostics. Noteworthy actions...
Novartis Reignites Parkinson’s Push with $200M Arrowhead RNAi Deal
Novartis has inked a $200 million upfront licensing agreement with Arrowhead Pharmaceuticals to develop ARO-SNCA, an RNA interference therapy targeting alpha-synuclein for Parkinson’s disease and...
Ionis Pharmaceuticals Advances Triglyceride Drug with Phase 3 Wins
Ionis Pharmaceuticals announced positive Phase 3 data for olezarsen, its antisense drug targeting severe hypertriglyceridemia (sHTG). The pivotal CORE and CORE2 trials showed up to 72%...
Amgen Commits Over $600M to New US R&D Center
Amgen announced plans to invest more than $600 million to build a cutting-edge science and innovation center at its global headquarters in Thousand Oaks, California. The facility aims to...
Treeline Biosciences Surfaces with $200M Funding and Clinical Candidates
Treeline Biosciences, a stealth oncology biotech founded by veterans Josh Bilenker and Jeff Engelman, publicly disclosed its first clinical programs and a $200 million series A extension, bringing...
Mercy BioAnalytics Raises $59M to Advance Cancer Early Detection
Mercy BioAnalytics announced the close of a $59 million Series B round to support commercialization of its blood-based ovarian cancer tests designed for population screening and mass evaluation of...
FDA and NIH Launch Initiatives to Accelerate Rare Disease Gene Therapies
The FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have jointly proposed a new submission program aimed at simplifying the approval...
Novartis Deepens RNA Drug Portfolio through Deals with Chinese Biotech Argo
Novartis expanded its RNA medicine collaborations with Shanghai-based Argo Biopharma, licensing discovery-stage cardiovascular RNA therapeutics with $160 million upfront and potential for billions...
AI Designs Next-Gen Antibiotics to Combat Drug Resistance
Researchers at the University of Pennsylvania have developed AMP-Diffusion, an AI-driven generative model that creates tens of thousands of novel antimicrobial peptides to combat drug-resistant...